Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03565887 · ClinicalTrials.gov registry record · Phase 3
Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
A Phase 3 study, sponsored by RVL Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 164
- Enrollment target
NCT03565887: Completed Phase 3 study, sponsored by RVL Pharmaceuticals.
NCT03565887 is a Phase 3 study that has completed, run by RVL Pharmaceuticals. The registered enrollment target is 164 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03565887, a Phase 3 study, has completed, sponsored by RVL Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 164 participants
- Enrollment target
Study Summary
Phase 3 study to evaluate the safety and efficacy of treatment with RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
Primary Outcome
LPFT Total Score is the number of points seen in the top 4 rows on the LPFT. Possible scores range from 0 (no points seen) to 35 (all points seen).
Interventions
- DRUG RVL-1201
- OTHER Vehicle ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2018-06-28 |
| Est. Completion | 2019-04-22 |
| Phase | Phase 3 |
What the finished NCT03565887 record still lists
NCT03565887 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which RVL-1201 is the first listed.
NCT03565887 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03565887 about?
NCT03565887 is a clinical study titled "Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis". Phase 3 study to evaluate the safety and efficacy of treatment with RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
What is the current status of trial NCT03565887?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 164 participants. The study started on 2018-06-28. Estimated completion is 2019-04-22.
What interventions are being tested in trial NCT03565887?
The interventions under investigation include: RVL-1201 (DRUG), Vehicle ophthalmic solution (OTHER).
Who is sponsoring clinical trial NCT03565887?
This trial is sponsored by RVL Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03565887's enrollment target sits among peer trials
164 1470th of 2000 higher than 530 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI